Evidence map›Paper›PMID 33931104›Full record

ReviewLipids in health and disease2021

Paradigm shift: the primary function of the "Adiponectin Receptors" is to regulate cell membrane composition.

Marc Pilon

Open access · goldAbstract readReview
In one paragraph

Review in Lipids in health and disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 34 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Regulation and Role of Adiponectin Secretion in Rat Ovarian Granulosa Cells.International journal of molecular sciences · 2024
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Marc PilonDept. Chemistry and Molecular Biology, Univ. Gothenburg, Box 462, S-405 30, Gothenburg, Sweden. marc.pilon@cmb.gu.se.
University of Gothenburg · SE

Funding

Cancerfonden CancerfondenCarl Tryggers Stiftelse för Vetenskaplig Forskning Carl Tryggers Stiftelse för Vetenskaplig ForskningDiabetesfonden DiabetesfondenStiftelsen för Strategisk Forskning Stiftelsen för Strategisk ForskningVetenskapsrådet Vetenskapsrådet
6 · The paper itself

Abstract

The ADIPOR1 and ADIPOR2 proteins (ADIPORs) are generally considered as adiponectin receptors with anti-diabetic properties. However, studies on the yeast and C. elegans homologs of the mammalian ADIPORs, and of the ADIPORs themselves in various mammalian cell models, support an updated/different view. Based on findings in these experimental models, the ADIPORs are now emerging as evolutionarily conserved regulators of membrane homeostasis that do not require adiponectin to act as membrane fluidity sensors and regulate phospholipid composition. More specifically, membrane rigidification activates ADIPOR signaling to promote fatty acid desaturation and incorporation of polyunsaturated fatty acids into membrane phospholipids until fluidity is restored. The present review summarizes the evidence supporting this new view of the ADIPORs, and briefly examines physiological consequences.

Indexed as

AnimalsCaenorhabditis elegansCell MembraneHumansReceptors, AdiponectinSaccharomyces cerevisiaeADIPOR1 protein, humanADIPOR2 protein, humanReceptors, AdiponectinAdiponectin receptorCaenorhabditis elegansCeramidaseDesaturaseFatty acidLipid metabolismLRIGMembrane fluidityPAQRPhospholipid

Identifiers

PMID33931104
PMCPMC8088037
OpenAlexW3159262223

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.